Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Enterprise Value (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Enterprise Value for 4 consecutive years, with -$117.1 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 38.13% to -$117.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$117.1 million through Dec 2025, up 38.13% year-over-year, with the annual reading at -$117.1 million for FY2025, 38.13% up from the prior year.
  • Enterprise Value for Q4 2025 was -$117.1 million at Century Therapeutics, up from -$204.2 million in the prior quarter.
  • The five-year high for Enterprise Value was -$117.1 million in Q4 2025, with the low at -$415.3 million in Q2 2024.
  • Average Enterprise Value over 4 years is -$256.4 million, with a median of -$227.7 million recorded in 2025.
  • The sharpest move saw Enterprise Value soared 58.71% in 2023, then tumbled 165.54% in 2024.
  • Over 4 years, Enterprise Value stood at -$315.5 million in 2022, then dropped by 21.14% to -$382.2 million in 2023, then soared by 50.47% to -$189.3 million in 2024, then surged by 38.13% to -$117.1 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$117.1 million, -$204.2 million, and -$251.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.